Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Long-Term Investments (2019 - 2025)

Intellia Therapeutics (NTLA) has disclosed Long-Term Investments for 6 consecutive years, with $22.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments rose 291.66% to $22.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $22.5 million, a 291.66% increase, with the full-year FY2024 number at $260.2 million, up 1662.97% from a year prior.
  • Long-Term Investments was $22.5 million for Q3 2025 at Intellia Therapeutics, roughly flat from $22.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $350.5 million in Q3 2021 to a low of $5.7 million in Q3 2024.
  • A 5-year average of $64.2 million and a median of $27.5 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: tumbled 89.45% in 2022, then skyrocketed 1662.97% in 2024.
  • Intellia Therapeutics' Long-Term Investments stood at $58.1 million in 2021, then grew by 19.28% to $69.3 million in 2022, then crashed by 78.71% to $14.8 million in 2023, then surged by 1662.97% to $260.2 million in 2024, then crashed by 91.36% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Long-Term Investments are $22.5 million (Q3 2025), $22.5 million (Q2 2025), and $260.2 million (Q4 2024).